Management of meningitis due to antibiotic-resistant Acinetobacter species

The Lancet Infectious Diseases

Volumn 9, Issue 4, 2009, Pages 245-255

  Kim, Baek Nam ^a,c   Peleg, Anton Y ^d   Lodise, Thomas P ^e   Lipman, Jeffrey ^a,b   Li, Jian ^f   Nation, Roger ^f   Paterson, David L ^a,g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c Inje University College of Medicine   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

^e ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^f MONASH UNIVERSITY   (Australia)

^g Centre for Healthcare Related Infection Surveillance and Prevention (CRISP)   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DEXAMETHASONE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; POLYMYXIN; POLYMYXIN B; RIFAMPICIN; SULBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL MENINGITIS; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEUROSURGERY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION;

ACINETOBACTER; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MENINGITIS, BACTERIAL;

EID: 62749144052     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70055-6     Document Type: Review

References (161)

1. Karageorgopoulos D.E., and Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8 (2008) 751-762
2. Perez F., Hujer A.M., Hujer K.M., Decker B.K., Rather P.N., and Bonomo R.A. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007) 3471-3484
3. Peleg A.Y., Seifert H., and Paterson D.L. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21 (2008) 538-582
4. Dijkshoorn L., Nemec A., and Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 5 (2007) 939-951
5. Durand M.L., Calderwood S.B., Weber D.J., et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 328 (1993) 21-28
6. Aronin S.I., Peduzzi P., and Quagliarello V.J. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 129 (1998) 862-869
7. Hussein A.S., and Shafran S.D. Acute bacterial meningitis in adults. A 12-year review. Medicine (Baltimore) 79 (2000) 360-368
8. Lu C.H., Chang W.N., and Chang H.W. Adult bacterial meningitis in southern Taiwan: epidemiologic trend and prognostic factors. J Neurol Sci 182 (2000) 36-44
9. McMillan D.A., Lin C.Y., Aronin S.I., and Quagliarello V.J. Community-acquired bacterial meningitis in adults: categorization of causes and timing of death. Clin Infect Dis 33 (2001) 969-975
10. van de Beek D., de Gans J., Spanjaard L., Weisfelt M., Reitsma J.B., and Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 351 (2004) 1849-1859
11. Husain E., Chawla R., Dobson S., and Dele Davies H. Epidemiology and outcome of bacterial meningitis in Canadian children: 1998-1999. Clin Invest Med 29 (2006) 131-135
12. Weisfelt M., van de Beek D., Spanjaard L., and de Gans J. Nosocomial bacterial meningitis in adults: a prospective series of 50 cases. J Hosp Infect 66 (2007) 71-78
13. Rudinsky B., Stankovic I., Kacerova A., et al. Nosocomial postsurgical meningitis in children: a 12-year survey comparing data from 1993-1998 with data from 1999-2004. Infect Control Hosp Epidemiol 27 (2006) 788-790
14. Sacar S., Turgut H., Toprak S., et al. A retrospective study of central nervous system shunt infections diagnosed in a university hospital during a 4-year period. BMC Infect Dis 6 (2006) 43
15. Metan G., Alp E., Aygen B., and Sumerkan B. Carbapenem-resistant Acinetobacter baumannii: an emerging threat for patients with post-neurosurgical meningitis. Int J Antimicrob Agents 29 (2007) 112-113
16. Ho Y.H., Wang L.S., Chao H.J., Chang K.C., and Su C.F. Successful treatment of meningitis caused by multidrug-resistant Acinetobacter baumannii with intravenous and intrathecal colistin. J Microbiol Immunol Infect 40 (2007) 537-540
17. Wadi J.A., and Al Rub M.A. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med 27 (2007) 456-458
18. Paramythiotou E., Karakitsos D., Aggelopoulou H., Sioutos P., Samonis G., and Karabinis A. Post-surgical meningitis due to multiresistant Acinetobacter baumannii. Effective treatment with intravenous and/or intraventricular colistin and therapeutic dilemmas. Med Mal Infect 37 (2007) 124-125
19. Al Shirawi N., Memish Z.A., Cherfan A., and Al Shimemeri A. Post-neurosurgical meningitis due to multidrug-resistant Acinetobacter baumanii treated with intrathecal colistin: case report and review of the literature. J Chemother 18 (2006) 554-558
20. Ng J., Gosbell I.B., Kelly J.A., Boyle M.J., and Ferguson J.K. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. J Antimicrob Chemother 58 (2006) 1078-1081
21. Buke C., Sipahi O.R., Yurtseven T., and Zileli M. High dose of intrathecal netilmicin in the treatment of nosocomial Acinetobacter baumannii meningitis. J Infect 51 (2005) 420-422
22. Sueke H., Marsh H., and Dhital A. Using intrathecal colistin for multidrug resistant shunt infection. Br J Neurosurg 19 (2005) 51-52
23. Gleeson T., Petersen K., and Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J Antimicrob Chemother 56 (2005) 602-603
24. Fulnecky E.J., Wright D., Scheld W.M., Kanawati L., and Shoham S. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. J Infect 51 (2005) e249-e251
25. Kasiakou S.K., Rafailidis P.I., Liaropoulos K., and Falagas M.E. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. J Infect 50 (2005) 348-352
26. Bukhary Z., Mahmood W., Al-Khani A., and Al-Abdely H.M. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Med J 26 (2005) 656-658
27. deFreitas D.J., and McCabe J.P. Acinetobacter baumanii meningitis: a rare complication of incidental durotomy. J Spinal Disord Tech 17 (2004) 115-116
28. Benifla M., Zucker G., Cohen A., and Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. J Antimicrob Chemother 54 (2004) 290-292
29. Kendirli T., Aydin H.I., Hacihamdioglu D., et al. Meningitis with multidrug-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. J Hosp Infect 56 (2004) 328
30. Jimenez-Mejias M.E., Pichardo-Guerrero C., Marquez-Rivas F.J., Martin-Lozano D., Prados T., and Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 21 (2002) 212-214
31. Cawley M.J., Suh C., Lee S., and Ackerman B.H. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy 22 (2002) 527-532
32. Jimenez-Mejias M.E., Becerril B., Marquez-Rivas F.J., Pichardo C., Cuberos L., and Pachon J. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 19 (2000) 970-971
33. Chang W.N., Lu C.H., Huang C.R., and Chuang Y.C. Community-acquired Acinetobacter meningitis in adults. Infection 28 (2000) 395-397
34. Chang W.N., Lu C.H., Huang C.R., and Chuang Y.C. Mixed infection in adult bacterial meningitis. Infection 28 (2000) 8-12
35. Vasen W., Desmery P., Ilutovich S., and Di Martino A. Intrathecal use of colistin. J Clin Microbiol 38 (2000) 3523
36. Krcmery Jr. V., Filka J., Uher J., et al. Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diagn Microbiol Infect Dis 35 (1999) 75-80
37. Venkataraman S., George V., Jesudason M., and Ganesh A. Acinetobacter meningitis following head trauma. J Assoc Physicians India 47 (1999) 1020-1021
38. Lu C.H., Chang W.N., and Chuang Y.C. Resistance to third-generation cephalosporins in adult gram-negative bacillary meningitis. Infection 27 (1999) 208-211
39. Fernandez-Viladrich P., Corbella X., Corral L., Tubau F., and Mateu A. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis 28 (1999) 916-917
40. Nunez M.L., Martinez-Toldos M.C., Bru M., Simarro E., Segovia M., and Ruiz J. Appearance of resistance to meropenem during the treatment of a patient with meningitis by acinetobacter. Scand J Infect Dis 30 (1998) 421-423
41. Jimenez-Mejias M.E., Pachon J., Becerril B., Palomino-Nicas J., Rodriguez-Cobacho A., and Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 24 (1997) 932-935
42. Seifert H., Richter W., and Pulverer G. Clinical and bacteriological features of relapsing shunt-associated meningitis due to Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 14 (1995) 130-134
43. Sarma P.S., and Mohanty S. Mixed meningitis: association of Acinetobacter calcoaceticus var lwoffi and Streptococcus faecium. Postgrad Med J 71 (1995) 295-296
44. Nguyen M.H., Harris S.P., Muder R.R., and Pasculle A.W. Antibiotic-resistant acinetobacter meningitis in neurosurgical patients. Neurosurgery 35 (1994) 851-855 discussion 855.
45. Reindersma P., Nohlmans L., and Korten J.J. Acinetobacter, an infrequent cause of community acquired bacterial meningitis. Clin Neurol Neurosurg 95 (1993) 71-73
46. Jindal N., Arora S., and Prabhakar H. Acinetobacter anitratus-bacteremia with meningitis. Case report. Indian J Med Sci 43 (1989) 294-296
47. Mancebo J., Domingo P., Blanch L., Coll P., Net A., and Nolla J. Post-neurosurgical and spontaneous gram-negative bacillary meningitis in adults. Scand J Infect Dis 18 (1986) 533-538
48. Kobayashi T.K., Yamaki T., Yoshino E., et al. Meningitis with Acinetobacter calcoaceticus in cerebrospinal fluid. A case report. Acta Cytol 27 (1983) 281-284
49. Berkowitz F.E. Acinetobacter meningitis - a diagnostic pitfall. A report of 3 cases. S Afr Med J 61 (1982) 448-449
50. Lim V.K., and Talib S. A case of neonatal meningitis caused by Acinetobacter calcoaceticus var anitratus. Med J Malaysia 37 (1982) 11-13
51. Morgan M.E., and Hart C.A. Acinetobacter meningitis: acquired infection in a neonatal intensive care unit. Arch Dis Child 57 (1982) 557-559
52. Berk S.L., and McCabe W.R. Meningitis caused by Acinetobacter calcoaceticus var anitratus. A specific hazard in neurosurgical patients. Arch Neurol 38 (1981) 95-98
53. Ghoneim A.T., and Halaka A. Meningitis due to Acinetobacter calcoaceticus variant anitratus. J Hosp Infect 1 (1980) 359-361
54. Sachdev H.S., and Deb M. Acinetobacter meningitis: case report with review of literature. Indian Pediatr 17 (1980) 551-555
55. Guardado A.R., Blanco A., Asensi V., et al. Multidrug-resistant acinetobacter meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. J Antimicrob Chemother 61 (2008) 908-913
56. Huttova M., Freybergh P.F., Rudinsky B., et al. Postsurgical meningitis caused by Acinetobacter baumannii associated with high mortality. Neuro Endocrinol Lett 28 suppl 2 (2007) 15-16
57. Metan G., Alp E., Aygen B., and Sumerkan B. Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 60 (2007) 197-199
58. Siegman-Igra Y., Bar-Yosef S., Gorea A., and Avram J. Nosocomial acinetobacter meningitis secondary to invasive procedures: report of 25 cases and review. Clin Infect Dis 17 (1993) 843-849
59. Chen S.F., Chang W.N., Lu C.H., et al. Adult acinetobacter meningitis and its comparison with non-acinetobacter gram-negative bacterial meningitis. Acta Neurol Taiwan 14 (2005) 131-137
60. Chen H.P., Lai C.H., Chan Y.J., Chen T.L., Liu C.Y., and Fung C.P. Clinical significance of Acinetobacter species isolated from cerebrospinal fluid. Scand J Infect Dis 37 (2005) 669-675
61. Kralinsky K., Krcmeryova T., Tuharsky J., and Krcmery V. Nosocomial acinetobacter meningitis. Pediatr Infect Dis J 19 (2000) 270-271
62. Filka J., Huttova M., Schwartzova D., et al. Nosocomial meningitis due to Acinetobacter calcoaceticus in 10 children after ventriculoperitoneal shunt insertion. J Hosp Infect 44 (2000) 76-77
63. Korinek A.M., Baugnon T., Golmard J.L., van Effenterre R., Coriat P., and Puybasset L. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 59 (2006) 126-133 discussion 126-33.
64. Kourbeti I.S., Jacobs A.V., Koslow M., Karabetsos D., and Holzman R.S. Risk factors associated with postcraniotomy meningitis. Neurosurgery 60 (2007) 317-325 discussion 325-26.
65. Federico G., Tumbarello M., Spanu T., et al. Risk factors and prognostic indicators of bacterial meningitis in a cohort of 3580 postneurosurgical patients. Scand J Infect Dis 33 (2001) 533-537
66. Reichert M.C., Medeiros E.A., and Ferraz F.A. Hospital-acquired meningitis in patients undergoing craniotomy: incidence, evolution, and risk factors. Am J Infect Control 30 (2002) 158-164
67. Cunha B.A., Visvalingam B., and Yannelli B. Pseudomeningitis caused by Acinetobacter baumannii. Am J Infect Control 27 (1999) 179-181
68. Gusten W.M., Hansen E.A., and Cunha B.A. Acinetobacter baumannii pseudomeningitis. Heart Lung 31 (2002) 76-78
69. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 39 (2004) 1267-1284
70. Norrby S.R. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime. Am J Med 79 (1985) 56-61
71. Gales A.C., Jones R.N., and Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 12 (2006) 315-321
72. Modai J., Vittecoq D., Decazes J.M., Wolff M., and Meulemans A. Penetration of ceftazidime into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob Agents Chemother 24 (1983) 126-128
73. Nau R., Prange H.W., Kinzig M., et al. Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies. Antimicrob Agents Chemother 40 (1996) 763-766
74. Lodise T.P., Nau R., Kinzig M., Drusano G.L., Jones R.N., and Sorgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother 60 (2007) 1038-1044
75. Lutsar I., McCracken Jr. G.H., and Friedland I.R. Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 27 (1998) 1117-1127 quiz 1128-29.
76. Leggett J.E., Ebert S., Fantin B., and Craig W.A. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 74 (1990) 179-184
77. Leggett J.E., Fantin B., Ebert S., et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159 (1989) 281-292
78. Lutsar I., Ahmed A., Friedland I.R., et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 41 (1997) 2414-2417
79. Lutsar I., and Friedland I.R. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 39 (2000) 335-343
80. Andes D.R., and Craig W.A. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 13 (1999) 595-618
81. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26 (1998) 1-10 quiz 11-12.
82. Drusano G.L. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2 (2004) 289-300
83. Craig W.A. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22 (1995) 89-96
84. Craig W.A., and Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 15 (1996) 255-259
85. Sable C.A., and Scheld W.M. Theoretical and practical considerations of antibiotic therapy for bacterial meningitis. Antibiot Chemother 45 (1992) 96-117
86. Nau R., Sorgel F., and Prange H.W. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 35 (1998) 223-246
87. Nau R., and Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15 (2002) 95-110
88. Jones R.N., Sader H.S., and Beach M.L. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative gram-negative bacilli isolated in the SENTRY antimicrobial surveillance program (1997-2001). Int J Antimicrob Agents 22 (2003) 551-556
89. Jones R.N., Mendes C., Turner P.J., and Masterton R. An overview of the meropenem yearly susceptibility test information collection (MYSTIC) program: 1997-2004. Diagn Microbiol Infect Dis 53 (2005) 247-256
90. Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from the meropenem yearly susceptibility test information collection program (USA). Diagn Microbiol Infect Dis 56 (2006) 57-62
91. Rhomberg P.R., and Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 57 (2007) 207-215
92. Turner P.J. MYSTIC (meropenem yearly susceptibility test information collection): a global overview. J Antimicrob Chemother 46 suppl B (2000) 9-23
93. Turner P.J. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC programme (1997-2003). Diagn Microbiol Infect Dis 50 (2004) 291-293
94. Turner P.J. Use of a program-specific website to disseminate surveillance data obtained from the meropenem yearly susceptibility test information collection (MYSTIC) study. Diagn Microbiol Infect Dis 53 (2005) 273-279
95. Turner P.J. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC program. Diagn Microbiol Infect Dis 56 (2006) 341-344
96. Lodise Jr. T.P., Rhoney D.H., Tam V.H., McKinnon P.S., and Drusano G.L. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis 54 (2006) 223-230
97. Rhoney D.H., Tam V.H., Parker Jr. D., McKinnon P.S., and Coplin W.M. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy 23 (2003) 310-314
98. Chow K.M., Szeto C.C., Hui A.C., Wong T.Y., and Li P.K. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 23 (2003) 369-373
99. Lam S., and Gomolin I.H. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 26 (2006) 1169-1174
100. Ferrara N., Abete P., Giordano M., et al. Neurotoxicity induced by cefepime in a very old hemodialysis patient. Clin Nephrol 59 (2003) 388-390
101. Capparelli F.J., Diaz M.F., Hlavnika A., Wainsztein N.A., Leiguarda R., and Del Castillo M.E. Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function. Neurology 65 (2005) 1840
102. Sonck J., Laureys G., and Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 23 (2008) 966-970
103. Maganti R., Jolin D., Rishi D., and Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 8 (2006) 312-314
104. Martinez-Rodriguez J.E., Barriga F.J., Santamaria J., et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 111 (2001) 115-119
105. Mushtaq S., Ge Y., and Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases. Antimicrob Agents Chemother 48 (2004) 1313-1319
106. Linden P. Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem. Drug Saf 30 (2007) 657-668
107. Horiuchi M., Kimura M., Tokumura M., Hasebe N., Arai T., and Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 222 (2006) 114-124
108. Nau R., Lassek C., Kinzig-Schippers M., Thiel A., Prange H.W., and Sorgel F. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother 42 (1998) 2012-2016
109. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of doripenem vs. imipenem for ventilator-associated pneumonia. 47th Interscience conference on antimicrobial agents and chemotherapy; Chicago, IL, USA; Sept 17-20, 2007. L-486.
110. Drusano GL, Sorgel F, Quinn J, Mason B, Melnick D. Impact of pharmacodynamic dosing of meropenem on emergence of resistance during treatment of ventilator-associated pneumonia: a prospective clinical trial. 45th Interscience conference on antimicrobial agents and chemotherapy; Washington, DC, USA; Dec 16-19, 2005. K-127.
111. Scheetz M.H., Qi C., Warren J.R., et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51 (2007) 1621-1626
112. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis 8 suppl 5 (1986) S503-S511
113. Hanninen P., and Rossi T. Penetration of sulbactam into cerebrospinal fluid of patients with viral meningitis or without meningitis. Rev Infect Dis 8 suppl 5 (1986) S609-S611
114. Campoli-Richards D.M., and Brogden R.N. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 33 (1987) 577-609
115. Stahl J.P., Bru J.P., Fredj G., Brammer K.W., Malleret M.R., and Micoud M. Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy. Rev Infect Dis 8 suppl 5 (1986) S612-S616
116. Levin A.S., Levy C.E., Manrique A.E., Medeiros E.A., and Costa S.F. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 21 (2003) 58-62
117. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing; eighteenth edition informational supplement M100-S18 (2008), CLSI, Wayne, PA, USA
118. Soussy C.J., Cluzel M., Ploy M.C., et al. In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study. J Antimicrob Chemother 43 suppl C (1999) 43-50
119. Pfaller M.A., Sader H.S., Fritsche T.R., and Jones R.N. Antimicrobial activity of cefepime tested against ceftazidime-resistant Gram-negative clinical strains from North American hospitals: report from the SENTRY antimicrobial surveillance program (1998-2004). Diagn Microbiol Infect Dis 56 (2006) 63-68
120. Schonwald S., Beus I., Lisic M., Car V., and Gmajnicki B. Ciprofloxacin in the treatment of gram-negative bacillary meningitis. Am J Med 87 (1989) 248S-249S
121. Dagan R., Schlaeffer F., and Einhorn M. Parenteral fluoroquinolones in children with life-threatening infections. Infection 18 (1990) 237-238
122. Sinner S.W., and Tunkel A.R. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 18 (2004) 581-602 ix.
123. Lipman J., Allworth A., and Wallis S.C. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 31 (2000) 1131-1133
124. Forrest A., Nix D.E., Ballow C.H., Goss T.F., Birmingham M.C., and Schentag J.J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37 (1993) 1073-1081
125. Wong-Beringer A., Beringer P., and Lovett M.A. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin. Clin Infect Dis 25 (1997) 936-937
126. Frei C.R., and Burgess D.S. Pharmacodynamic analysis of ceftriaxone, gatifloxacin, and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation. Pharmacotherapy 25 (2005) 1161-1167
127. Noreddin A.M., Hoban D.J., and Zhanel G.G. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 26 (2005) 120-125
128. Pea F., Pavan F., Nascimben E., et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 47 (2003) 3104-3108
129. Scotton P.G., Pea F., Giobbia M., Baraldo M., Vaglia A., and Furlanut M. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clin Infect Dis 33 (2001) e109-e111
130. Viale P., Furlanut M., Cristini F., Cadeo B., Pavan F., and Pea F. Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis. Diagn Microbiol Infect Dis 58 (2007) 137-139
131. Rahal Jr. J.J., Hyams P.J., Simberkoff M.S., and Rubinstein E. Combined intrathecal and intramuscular gentamicin for gram-negative meningitis. Pharmacologic study of 21 patients. N Engl J Med 290 (1974) 1394-1398
132. Kaiser A.B., and McGee Z.A. Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med 293 (1975) 1215-1220
133. Bruckner O., Alexander M., and Collmann H. Tobramycin levels in cerebrospinal fluid of patients with slightly and severely impaired blood-cerebrospinal barrier. Chemotherapy 27 (1981) 303-308
134. Wright P.F., Kaiser A.B., Bowman C.M., McKee Jr. K.T., Trujillo H., and McGee Z.A. The pharmacokinetics and efficacy of an aminoglycoside administered into the cerebral ventricles in neonates: implications for further evaluation of this route of therapy in meningitis. J Infect Dis 143 (1981) 141-147
135. Klastersky J., Mombelli G., Coppens L., Daneau D., and Brihaye J. Post neurosurgery gram-negative bacillary meningitis. J Infect 3 1 suppl (1981) 45-51
136. Rea R.S., and Capitano B. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 28 (2007) 596-603
137. Lorber J., Kalhan S.C., and Mahgrefte B. Treatment of ventriculitis with gentamicin and cloxacillin in infants born with spina bifida. Arch Dis Child 45 (1970) 178-185
138. Kourtopoulos H., and Holm S.E. Intraventricular treatment of Serratia marcescens meningitis with gentamicin. Pharmacokinetic studies of gentamicin concentration in one case. Scand J Infect Dis 8 (1976) 57-60
139. Welch K. Residual shunt infection in a program aimed at its prevention. Z Kinderchir Grenzgeb 28 (1979) 374-377
140. Hollifield J.W., Kaiser A.B., and McGee Z.A. Gram-negative bacillary meningitis therapy. Polyradiculitis following intralumbar aminoglycoside administration. JAMA 236 (1976) 1264-1266
141. Wirt T.C., McGee Z.A., Oldfield E.H., and Meacham W.F. Intraventricular administration of amikacin for complicated gram-negative meningitis and ventriculitis. J Neurosurg 50 (1979) 95-99
142. de Champs C., Guelon D., Joyon D., Sirot D., Chanal M., and Sirot J. Treatment of a meningitis due to an Enterobacter aerogenes producing a derepressed cephalosporinase and a Klebsiella pneumoniae producing an extended-spectrum beta-lactamase. Infection 19 (1991) 181-183
143. Corpus K.A., Weber K.B., and Zimmerman C.R. Intrathecal amikacin for the treatment of pseudomonal meningitis. Ann Pharmacother 38 (2004) 992-995
144. Li J., Nation R.L., Turnidge J.D., et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 6 (2006) 589-601
145. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., and Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53 (2004) 837-840
146. Levin A.S., Barone A.A., Penco J., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28 (1999) 1008-1011
147. Falagas M.E., Bliziotis I.A., and Tam V.H. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 29 (2007) 9-25
148. Petrosillo N., Chinello P., Proietti M.F., et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11 (2005) 682-683
149. Motaouakkil S., Charra B., Hachimi A., et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53 (2006) 274-278
150. Pachon-Ibanez M.E., Fernandez-Cuenca F., Docobo-Perez F., Pachon J., and Pascual A. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. J Antimicrob Chemother 58 (2006) 689-692
151. Saballs M., Pujol M., Tubau F., et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58 (2006) 697-700
152. Hogg G.M., Barr J.G., and Webb C.H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 41 (1998) 494-495
153. Tascini C., Menichetti F., Bozza S., Del Favero A., and Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 42 (1998) 270-271
154. Li J., Nation R.L., Owen R.J., Wong S., Spelman D., and Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45 (2007) 594-598
155. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., and Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58 (2006) 1221-1229
156. Wen D.Y., Bottini A.G., Hall W.A., and Haines S.J. Infections in neurologic surgery. The intraventricular use of antibiotics. Neurosurg Clin N Am 3 (1992) 343-354
157. Chaudhuri A. Adjunctive dexamethasone treatment in acute bacterial meningitis. Lancet Neurol 3 (2004) 54-62
158. Rodriguez-Bano J., Marti S., Soto S., et al. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. Clin Microbiol Infect 14 (2008) 276-278
159. Kaufman B.A. Infections of cerebrospinal fluid shunts. In: Scheld W.M., Whitley R.J., and Durack D.T. (Eds). Infections of the central nervous system. 2nd edn. (1997), Lippincott-Raven, Philadelphia 555-577
160. Coly-Mycin M Parenteral package insert. Monarch Pharmaceuticals. Bristol, TN, USA, 2005.
161. Polymyxin B for injection package insert. Bedford Laboratories. Bedford, OH, USA, 2004.